Published • loading... • Updated
Eye Cancer's Hidden Weakness: CRISPR Screens Expose p300 as a Lifeline
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Eye Cancer's Hidden Weakness: CRISPR Screens Expose p300 as a Lifeline
CRISPR-based synthetic lethal screening has identified the acetyltransferases p300 and CBP as essential chromatin partners for YAP-driven transcription in GNAQ-mutant uveal melanoma, pointing to a new therapeutic target for this hard-to-treat eye cancer.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
